IRON Stock Analysis: Disc Medicine | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.863m USD | 12M Return: 39.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.4M
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious hematologic diseases. Founded in 2017 and headquartered in Watertown, Massachusetts, the company targets fundamental biological pathways involved in red blood cell formation and function, particularly heme biosynthesis and iron homeostasis. Its pipeline spans multiple candidates, including bitopertin for erythropoietic porphyrias and Diamond-Blackfan anemia, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, DISC-3405 for polycythemia vera, and preclinical program DISC-0998 for anemia linked to inflammatory diseases.
As a clinical-stage biotechnology company in the mid-cap segment, Disc Medicine operates in a sector characterized by lengthy drug development timelines, significant R&D investment, and revenue dependent on eventual product approvals, partnerships, or licensing agreements rather than commercial sales. The companys focus on hematology places it within a specialized therapeutic area where treatments often address rare or chronic blood disorders with limited existing therapeutic options, a niche that has historically attracted both venture capital investment and larger pharmaceutical partnership interest.
- Bitopertin phase 3 data readout for erythropoietic porphyria nears
- DISC-0974 anemia program advances in myelofibrosis and CKD trials
- Cash burn and equity dilution risk amid clinical pipeline spending
| Net Income: -241.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -12.32 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 > 3% & CFO -201.3m > Net Income -241.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.5m) vs 12m ago 15.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: -1.64% > 50% (prev 0.0%; Δ -1.64% > 0%) |
| Interest Coverage Ratio: -67.14 > 6 (EBIT TTM -238.6m / Interest Expense TTM 3.55m) |
| A: 0.95 (Total Current Assets 747.5m - Total Current Liabilities 31.1m) / Total Assets 750.2m |
| B: -0.76 (Retained Earnings -573.7m / Total Assets 750.2m) |
| C: -0.33 (EBIT TTM -238.6m / Avg Total Assets 729.7m) |
| D: 11.14 (Book Value of Equity 688.4m / Total Liabilities 61.8m) |
| Altman-Z'' = 13.27 = AAA |
As of July 04, 2026, the stock is trading at USD 76.26 with a total of 985,700 shares traded. Over the past week, the price has changed by +8.69%, over one month by +8.40%, over three months by +15.86% and over the past year by +39.29%.
Current recommended Stop Loss: 68.60 (which is 10% or 2.5 ATR below the current price).
Disc Medicine has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy IRON.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 101.6 | 33.2% |
P/B = 4.1593
Revenue TTM = -12.0m USD
EBIT TTM = -238.6m USD
EBITDA TTM = -238.2m USD
Long Term Debt = 29.4m USD (from longTermDebt, last quarter)
Short Term Debt = 419k USD (from shortTermDebt, last quarter)
Debt = 32.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.70m
Net Debt = -697.4m USD (calculated: Debt 32.8m - CCE 730.2m)
Enterprise Value = 2.17b USD (2.86b + Debt 32.8m - CCE 730.2m)
Interest Coverage Ratio = -67.14 (Ebit TTM -238.6m / Interest Expense TTM 3.55m)
EV/FCF = -10.76x (Enterprise Value 2.17b / FCF TTM -201.3m)
FCF Yield = -9.30% (FCF TTM -201.3m / Enterprise Value 2.17b)
WARNING: Negative Revenue TTM = -12.0m
FCF Margin = 1.68k% (FCF TTM -201.3m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Net Margin = 2.02k% (Net Income TTM -241.6m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Gross Margin = unknown ((Revenue TTM -12.0m - Cost of Revenue TTM 350k) / Revenue TTM)
Tobins Q-Ratio = 2.89 (Enterprise Value 2.17b / Total Assets 750.2m)
Interest Expense / Debt = 10.85% (Interest Expense 3.55m / Debt 32.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -188.5m (EBIT -238.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.00 (Total Current Assets 747.5m / Total Current Liabilities 31.1m)
Debt / Equity = 0.05 (Debt 32.8m / totalStockholderEquity, last quarter 688.4m)
Debt / EBITDA = 2.93 (negative EBITDA) (Net Debt -697.4m / EBITDA -238.2m)
Debt / FCF = 3.46 (negative FCF - burning cash) (Net Debt -697.4m / FCF TTM -201.3m)
Total Stockholder Equity = 654.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.11% (Net Income -241.6m / Total Assets 750.2m)
RoE = -36.95% (Net Income TTM -241.6m / Total Stockholder Equity 654.0m)
RoCE = -34.92% (EBIT -238.6m / Capital Employed (Equity 654.0m + L.T.Debt 29.4m))
RoIC = -26.20% (negative operating profit) (NOPAT -188.5m / Invested Capital 719.5m)
WACC = 9.87% (E(2.86b)/V(2.90b) * Re(9.88%) + D(32.8m)/V(2.90b) * Rd(10.85%) * (1-Tc(0.21)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 24.37%
[DCF] Fair Price = unknown (Cash Flow -201.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.62 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.77 | Chg30d=-0.05% | Revisions=+10% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-1.86 | Chg30d=-0.26% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=-7.16 | Chg30d=-0.02% | Revisions=+0% | GrowthEPS=-19.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.59 | Chg30d=-1.07% | Revisions=+10% | GrowthEPS=-5.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +6% (up=16, down=14)